Comparative Pharmacology
Head-to-head clinical analysis: AVYCAZ versus CEFOTAXIME SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVYCAZ versus CEFOTAXIME SODIUM.
AVYCAZ vs CEFOTAXIME SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVYCAZ is a combination of ceftazidime, a cephalosporin beta-lactam antibiotic, and avibactam, a non-beta-lactam beta-lactamase inhibitor. Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis. Avibactam protects ceftazidime from degradation by certain beta-lactamases, including Ambler class A, class C, and some class D enzymes.
Cefotaxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-1A and PBP-3, leading to cell lysis and death.
1 vial (ceftazidime 2g and avibactam 0.5g) IV over 2 hours every 8 hours.
1-2 g IV/IM every 8 hours; maximum 12 g/day for severe infections.
None Documented
None Documented
Ceftazidime: ~2.8 hours; avibactam: ~2.7 hours. Extended in renal impairment (e.g., CrCl <50 mL/min requires dose adjustment).
Terminal elimination half-life is 0.9-1.5 hours in adults with normal renal function; prolonged to 2.5-10 hours in renal impairment (CrCl <20 mL/min). In neonates, half-life is 3-6 hours.
Ceftazidime: primarily renal (80-90% unchanged); avibactam: primarily renal (85-95% unchanged). Fecal excretion <1%.
Renal (50-60% unchanged), biliary (5-10%), with approximately 20-30% metabolized to desacetylcefotaxime (also renally eliminated). Total renal elimination of parent drug and metabolite accounts for >80%.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic